CARMAT Provides an Update on the Ongoing Receivership Procedure
PARIS, September 29, 2025–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT“), today provides an update on the ongoing receivership procedure. Update on the ongoing receivership procedure Following a…

